AWM
VRTX icon

Apollon Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Apollon Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.7M Buy
63,910
+25,315
+66% +$11.2M 0.39% 52
2026
Q1 		$17.2M Buy
38,595
+9,400
+32% +$4.38M 0.28% 79
2025
Q4 		$13.2M Sell
29,195
-171
-0.6% -$73.7K 0.23% 91
2025
Q3 		$11.5M Sell
29,366
-391
-1% -$163K 0.2% 98
2025
Q2 		$13.2M Buy
29,757
+4,630
+18% +$2.13M 0.26% 73
2025
Q1 		$12.2M Buy
25,127
+12,955
+106% +$6.04M 0.27% 76
2024
Q4 		$4.9M Buy
12,172
+3,976
+49% +$1.84M 0.11% 160
2024
Q3 		$3.81M Buy
8,196
+793
+11% +$381K 0.11% 166
2024
Q2 		$3.47M Buy
7,403
+313
+4% +$136K 0.11% 173
2024
Q1 		$2.96M Buy
7,090
+730
+11% +$309K 0.09% 201
2023
Q4 		$2.59M Buy
6,360
+1,435
+29% +$530K 0.09% 207
2023
Q3 		$1.71M Buy
4,925
+378
+8% +$132K 0.09% 227
2023
Q2 		$1.6M Buy
4,547
+116
+3% +$39.1K 0.08% 264
2023
Q1 		$1.4M Sell
4,431
-231
-5% -$69.3K 0.09% 244
2022
Q4 		$1.35M Buy
4,662
+711
+18% +$217K 0.1% 224
2022
Q3 		$1.14M Buy
3,951
+598
+18% +$172K 0.09% 221
2022
Q2 		$945K Buy
3,353
+357
+12% +$95.6K 0.08% 274
2022
Q1 		$782K Buy
2,996
+551
+23% +$131K 0.06% 347
2021
Q4 		$537K Buy
+2,445
New +$475K 0.04% 444
2020
Q3 		– Sell
-16
Closed -$5K – 671
2020
Q2 		$5K Buy
+16
New +$4.34K ﹤0.01% 569

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Apollon Wealth Management's VRTX Position: Q2 2026 in Review

Apollon Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 66% in Q2 2026, buying an estimated $11.2M and bringing the position to 63,910 shares worth $31.7M. The position accounts for 0.39% of the portfolio, ranked #52.

Apollon Wealth Management first reported a position in VRTX in Q2 2020 and has held it in 20 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Apollon Wealth Management held 63,910 shares of Vertex Pharmaceuticals worth $31.7M as of Q2 2026.
  • Apollon Wealth Management bought 25,315 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.2M.
  • Vertex Pharmaceuticals made up 0.39% of Apollon Wealth Management's portfolio in Q2 2026, its #52 holding.
  • Apollon Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.